Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raymond Benza (Pittsburgh, United States of America), Raymond Benza, Adaani Frost, Harrison Farber, Hossein-Ardeschir Ghofrani, Miguel Angel Gómez Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia Nikkho, Marius Hoeper. Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study. Eur Respir J 2015; 46: Suppl. 59, 2102

Member's Comments

No comment yet.

Related content which might interest you: Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Characteristics of essential hypertension in COPD patients Source: International Congress 2014 – COPD: points to ponder Year: 2014 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Changes in inhalation therapy after combined assessment of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Pulmonary hypertension due to lung disease – Results from COMPERA Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015